^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MLL-MLLT3 fusion

    i
    Other names: HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Methyltransferase 2A, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Lysine Methyltransferase 2A, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, KMT2A, MLLT3, MLLT3 Super Elongation Complex Subunit, Myeloid/Lymphoid Or Mixed-Lineage L
    Entrez ID:
    4300
    Related biomarkers:
    Others
    3years
    Genomic Analysis of NPM1 Mutation and KMT2A (MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01 (ASH 2021)
    Approximately three in ten patients with AML had NPM1 mutation and/or KMT2A (MLL )-rearrangement/amplification. No single patient had both the alterations. FLT3 and DNA methylation-associated genes (e.g., DNMT3A and TET2 ) were frequently seen in patients with NPM1 mt.
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • NF1 (Neurofibromin 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • WT1 (WT1 Transcription Factor) • MLLT3 (MLLT3 Super Elongation Complex Subunit)
    |
    TP53 mutation • KRAS mutation • NPM1 mutation • DNMT3A mutation • KMT2A rearrangement • MLL rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation • MLL fusion • MLL-MLLT3 fusion • NPM1 W288
    |
    FoundationOne® Heme CDx